Xenikos
Nijmegen
About Xenikos
Xenikos aims to develop a new medicine, based on the action of antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $86.9M
- Funding stage: Early Stage Venture
- Last round: Grant (Dec 2022)
- Website: xenikos.com
- Phone: +31 24 300 01 00
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/xenikos-156509 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.